OIP AUG 30	5004 3 C						
FORM PTO			lodified)	APPLICATION NO.:	09/934,249	ATTY. DOCKET NO.: P0738.70001US00
INFO	RMA	TION I	DISCI	LOSURE	FILING DATE:	August 21, 2001	CONFIRMATION NO.: 6506
				LICANT	APPLICANT:	Richard T. Lee et	al.
			· ·		GROUP ART UNIT:	1648	EXAMINER: Zachariah Lucas
Sheet	ļ	1	of	3	1		

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document Number Kind		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY	
32	Al	5,217,899	Code	Shapiro, et al.	06/08/1993	
			i			

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of	Translation
	No.	Office/ Country	Number	Kind Code	Cited	Cited Document MM-DD-YYYY	(Y/N)
						ļ	<u></u>
	İ	ļ j		i			

Examiner's	Cite	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the letter	(Y/N)	
Initials	No	(book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s),	date, relevant page(s), volume-issue number(s),	
		publisher, city and/or country where published.		
2	C8	Arstall et al, "Human Ventricular Myocytes in vitro Exhibit Both Early and Delayed Preconditioning		
32		Responses to Simulated Ischemia," J Mol Cell Cardiol, Vol. 30, pp. 1019-25 (1998)		
	C9	Barbee et al, "Strain measurements in cultured vascular smooth muscle cells subjected to mechanical	j	
32	į .	deformation " Ann Biomed Eng 1994 22(1): 14-22		
/	C10	Carballo et al, "Bone Marrow Transplantation Reproduces the Tristetraprolin-Deficiency Syndrome		
22		in Recombination Activating Gene-2 (-/-) Mice," J Clin Invest, Vol. 100, No. 5, pp. 986-95 (1997)		
/	C11	Chen et al., "Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-		
32	-	hidroxyvitamin D-3." Biochim Biophys Acta 1219(1) 26-32, 1994		
	C12	Cheng, et al. "Mechanical Strain Tightly Controls Fibroblast Growth Factor-2 Release From Cultured		
32	1	Human Vascular Smooth Muscle Cells," Circ. Res. 1997; 80: 28-36.		
/	C13	Cortes et al, "BTG Gene Expression in the p53-Dependent and -Independent Cellular Response to		
32	1	DNA Damage." Molecular Carcinogenesis, Vol. 27, pp. 57-64 (2000)		
	C14	Geisterfer-Lowrance et al., "A mouse model of familial hypertrophic cardiomyopathy," Science]]	
32		1996 272: 731-734		
/	C15	Haloy et al "Overexpression of Eotaxin and the CCR3 Receptor in Human Atherosclerosis: using		
<u>.</u>	4	genomic technology to identify a potential novel pathway of vascular inflammation," Circulation,		
31		Vol. 102 pp. 2185-2189 (2000)		
/	C16	Hamada et al "Stretch Activates Jun N-terminal Kinase/Stress-activated Protein Kinase in Vascular	1	
•.	""	Smooth Muscle Cells through Mechanisms Involving Autocrine ATP Stimulation of Purinoceptors,"		
32		I Riol Chem. Vo. 273, No. 11, pp. 6334-6340 (1998)		
	C17	Johnson et al, "Similar but distinct effects of the tristetraprolin/TIS11 immediate-early proteins on		
32	"	cell survival." Oncogene, Vol. 19, pp. 1657-1664 (2000)		
	C18	Karas et al, "Human vascular smooth muscle cells contain functional estrogen receptor," Circulation	\	l
32	+ "	1994 80: 1943-50		
/	C19	Kave et al. "Role of Transiently Altered Sarcolemmal Membrane Permeability and Basic Fibroblast		l
_	"	Growth Factor Release in the Hypertrophic Response of Adult Rat Ventricular Myocytes to Increased	1 1	
32		Mechanical Activity In Vitro," J Clin Invest., Vol. 97, No. 2, pp. 281-91 (1996)	ļ	L
/	C20	Kobayashi et al, "Regulation of a Novel Immediate Early Response Gene, IEX-1, in Keratinocytes by		
30	020	1α, 25-Dihydroxyvitamin D ₃ ," Biochem Biophys Res Commun., Vol. 251, pp. 868-73 (1998)		L
		10, 23-Dilly Grovy vitalistic 23, Dioviolity 2007.		

gen u

2/24/05

Sheet

FORM PTO-1448 and B (Modified)

2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

APPLICATION NO.: 09/934,249

ATTY. DOCKET NO.: P0738.70001US00

August 21, 2001

CONFIRMATION NO.: 6506

APPLICANT:

FILING DATE:

Richard T. Lee et al.

GROUP ART UNIT: 1648

EXAMINER: Zachariah Lucas

Sheet		01	3	<u>, , , , , , , , , , , , , , , , , , , </u>						
			OTHER AR	T — NON PATENT LITERATURE DOCUMENTS	Transla					
Examiner's	Cite									
Initials	No	(book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s),								
				publisher, city and/or country where published.	 					
32	C21			ation and characterization of a radiation-inducible glycosylated human	j					
/	٠	early-respoi	ise gene," Cance	er Res 1996 56(7):1498-502	<u> </u>					
	C22		umar et al, "A Novel Immediate Early Response Gene, IEX-1, Is Induced by Ultraviolet Radiation							
32				Biochem Biophys Res Commun., Vol. 253, pp. 336-41 (1998)						
	C23	Lai et al, "E	vidence that Tri	stetraprolin Binds to AU-Rich Elements and Promotes the Deadenylation						
1 1	L	and Destabi	and Destabilization of Tumor Necrosis Factor Alpha mRNA," Mol Cell Biol Vol. 19, No. 6, pp.							
7			4311-23 (1999)							
	C24			n mediated by changes in the endothelial actin cytoskeleton" J. Clin.						
72		Invest., Vol. 106, No. 1, pp. 15-24 (2000)								
132	C25			rain system for cultured cells," Am J Physiol., pp. C1400-8 (1996)	1					
	C26			n homologue of the murine Tis11d early response gene," Gene	+					
12	620			in nomologue of the marine 113110 early response gene, Gene						
-5-	C27		p. 285-6 (1995)	tion of This adection him disconnection 200 terrois D. Un accounted J. D. and J. 1	++					
_	C27			tion of Thioredoxin-binding Protein-2/Vitamin D ₃ Up-regulated Protein 1						
				Thioredoxin Function and Expression". Journal of Biological Chemistry		ı				
3			o. 31, pp. 2 1645							
	C28			nioredoxin is a direct inhibitor of apoptosis signal-regulating kinase						
.52		(ASK) 1," I	EMBO Journal, '	Vo 17, No. 9, pp. 2596-2606 (1998)						
100	C29	Schafer et a	l, "The putative	apoptosis inhibitor IEX-1L is a mutant nonspliced variant of p22PRGI/JEX-1		1				
32		and is not e	xpressed in vivo	" Biochem Biophys Res Commun 1999, 262(1):139-45						
/	C30	Schafer et a	l, "Human PAC	AP response 1 gene (p22/PRG1): proliferation-associated expression in						
72				Pancreas 1999 18(4): 378-84	1					
	C31			r of human p22/PACAP response gene 1 (PRG1) contains functional						
32				nor suppressor and for NFkB," FEBS Lett 1998 436(2): 139-43		1				
-/	C32			vel early response gene transcriptionally induced by pituitary adenylate	\vdash					
32	032			de in a pancreatic carcinoma cell line," Cancer Res. 1996 56: 2641-2648						
	C22				 					
32	modulated 1 animaly, 3 Biol Chemi, 1 on 273, 110. 57, pp. 20371 20379 (2000)									
2										
7-	C34			thioredoxin is enhanced in atherosclerotic plaques and during neointima						
32				ab Invest 1998, 78:957-96	<u> </u>	<u> </u>				
/ , _	C35			role for TNFα in the syndrome of cachexia, arthritis, and autoimmunity	1	l				
32	·	resulting fro	om tristetraprolir	n (TTP) deficiency," Immunity 1996 May 4(5) 445-54						
22	C36			Ds: Two novel MAD-related genes selectively inducible by flow in						
5				n," PNAS, Vol. 94, pp. 9314-9319 (1997)						
	C37			tosis inhibitor involved in NF-kB-mediated cell survival," Science 1998						
32		281(5379):9			1	1				
	C38			vitamin D-regulated gene (VDUP-1) in untreated and MNU-treated rat						
22				ancer Res Treat, Vol. 48, pp. 33-44 (1998)						
122-	C39		sion No. Al76144	<u> </u>	 					
he	C40		sion No. AL1219		 	l				
/22	C41		sion No. AL1213.		 					
122	C42		sion No. NM 004		 					
1-21	C42		sion No. AQ1774		 					
132	C44		sion No. AL03554		 					
132	C45		sion No. X67644		 					
42	C46		sion No. AF1736	81	 					
32	C47		sion No. X77585		 	i				
36	C48		sion No. P46694		 					
	C49		sion No. U72649							

2/24/08

ATTY. DOCKET NO .: P0738.70001US00 APPLICATION NO.: 09/934,249 and B (Modified) CONFIRMATION NO.: 6506 INFORMATION DISCLOSURE FILING DATE: August 21, 2001 STATEMENT BY APPLICANT APPLICANT: Richard T. Lee et al. EXAMINER: Zachariah Lucas

1648

GROUP ART UNIT:

Sheet	3	of	-3	GROUP ART UNIT.	1048	EXAMINER: Busharian Bush	~		
3.1001	<u>-</u> _		OTHER A	RT — NON PATENT L	ITERATURE	DOCUMENTS			
Examiner's Initials	Cite No	Include n (book; m	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book; magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.						
22	C50		ssion No. M9284					 	
132	C51			(VDUP1/mRNA)				₩	
132	C52	NCBI Acce	ssion No. S8191	4					
72	C53	NCBI Acce	ssion No. AF0834	421			 	├ ─	
32	C54	NCBI Acce	NCBI Accession No. AF071596						
72	C55	NCBI Acce	NCBI Accession No. AF039067						
132	C56	NCBI Acce	NCBI Accessison No. Y14551						
132	C57	NCBI Acce	NCBI Accession No. NP 003888						
132	C58	NCBI Acce	NCBI Accession No. P46695						
132	C59	NCBI Acce	NCBI Accession No. NM 006472						
132	C60	NCBI Accession No. NP 006463							
132	C61	NCBI Acce	ssion No. H2836.	3				↓	
132	C62	NCBI Acce	NCBI Accession No. H28387						
100	C63	NCBI Acce	esion No. S73591	(MG068 homolog)			- 1		

EXAMINER 3	DATE CONSIDERED 2/24/05

#EXAMMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[[]NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]